SAM Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
SAM is not a good buy right now for an impatient investor looking for immediate upside. The setup is mildly bearish/indecisive (negative and worsening MACD, price below the pivot), insider selling is sharply elevated, and Street targets have been cut to levels that imply limited near-term upside (~$220 vs ~$211). I would stay on the sidelines unless it quickly reclaims the $215 pivot and then breaks/holds above $223 (R1), which would better align momentum with upside.
Trend/Momentum: Short-term momentum is weakening. MACD histogram is -0.729 (below zero) and negatively expanding, which typically confirms bearish momentum building rather than stabilizing. RSI(6) at 38.4 is not deeply oversold but leans weak (buyers not showing strong urgency).
Moving averages: Converging MAs suggest consolidation after a decline rather than a clean uptrend.
Key levels: Pivot 215.254 is the near-term line in the sand. Price (210.92) is below pivot, keeping bias cautious. Support levels sit at S1 207.635 then S2 202.928; a break below ~207.6 increases odds of a quick move toward ~203. Upside resistance is R1 222.873 then R2 227.58.
Pattern-based near-term drift: Similar-pattern stats suggest modest positive drift (next day +0.21%, next week +1.31%, next month +3.33%), but this is small relative to nearby resistance and the current negative momentum.
Intellectia Proprietary Trading Signals
Product/news catalyst: Samuel Adams launched Cherry Bomb (9% ABV) targeting the high-ABV category, which could support mix and brand buzz if it gains traction.
Profitability trend: Despite revenue decline, Q3 showed notable YoY improvements in net income, EPS, and gross margin—evidence cost/mix discipline can offset some volume pressure.
Technical upside trigger: A reclaim of ~215 followed by a break above ~223 could quickly shift near-term momentum from defensive to constructive.
Insider selling: Insiders are selling, and selling amount increased ~388% over the last month—this is a meaningful negative signal for near-term confidence.
Technical momentum: MACD is negative and deteriorating; price is below the pivot, raising the odds of a support retest at ~207.6 and possibly ~202.
Analyst sentiment/targets: Recent notes show Neutral stances and price target cuts (e.g., Citi $250→$220; Piper $230→$220), limiting perceived upside.
Event risk ahead: Next reported earnings (QDEC
on 2026-02-23 after hours with an EPS estimate of -2.32, which can keep buyers cautious and volatility elevated into the print.
Latest reported quarter: 2025/Q3. Growth trends: Revenue fell to $537.5M (-11.23% YoY), showing top-line contraction. However, profitability improved sharply: net income rose to $46.2M (+37.72% YoY) and EPS increased to 4.25 (+48.60% YoY). Gross margin expanded to 50.81% (+9.79% YoY). Bottom line: strong margin/profit improvement, but the revenue decline is a headwind and makes the near-term growth story less compelling.
Recent trend: Ratings are broadly Neutral with price targets moving down.
